TiGenix to participate in key investor conferences in April 2017
(Thomson Reuters ONE) -
PRESS RELEASE
TiGenix to participate in key investor conferences in April 2017
Leuven (BELGIUM) - April 5, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels
and NASDAQ: TIG), an advanced biopharmaceutical company developing and
commercializing novel therapeutics which exploit the anti-inflammatory
properties of allogeneic, or donor-derived, stem cells, today announces that its
management will be presenting at the 24(th) annual BioCentury Future Leaders in
the Biotech Industry, New York, USA, and the Alliance for Regenerative Medicine
(ARM) 5(th) Annual Cell and Gene Therapy Investor Day, Boston, USA. Tigenix will
also be attending the 10(th) Kempen & Co Life Sciences Conference, Amsterdam,
The Netherlands.
24(th) Annual BioCentury Future Leaders in the Biotech Industry
Date: Friday 7th April 2017
Venue: Millennium Broadway Hotel & Conference Center,
New York, U.S.
Presenter: Eduardo Bravo, Chief Executive Officer, Tigenix NV
10(th) Annual Kempen & Co Life Sciences Conference
Date: Wednesday 19th April 2017
Venue: Kempen & Co, Beethovenstraat 300, Amsterdam, The
Netherlands
Attendee: Eduardo Bravo, Chief Executive Officer, Tigenix
NV
Alliance for Regenerative Medicine (ARM) 5(th) Annual Cell and Gene Therapy
Investor Day
Date: Thursday 27th April 2017
Venue: The State Room, 60 State Street, Boston, U.S.
Presenter: Eduardo Bravo, Chief Executive Officer, Tigenix NV
For more information
Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta(at)tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels and NASDAQ: TIG) is a biopharmaceutical company
developing and commercializing novel therapeutics which exploit the anti-
inflammatory properties of allogeneic, or donor-derived, stem cells generated by
its proprietary platform technologies.
TiGenix's lead product, Cx601, has successfully completed a European Phase III
for the treatment of complex perianal fistulas - a severe, debilitating
complication of Crohn's disease. Cx601 has been filed for regulatory approval in
Europe and a global Phase III trial intended to support a future U.S. Biologic
License Application (BLA) is expected to start in 2017. TiGenix has entered into
a licensing agreement with Takeda, a large pharmaceutical company active in
gastroenterology, under which Takeda acquired the exclusive right to
commercialize Cx601 for complex perianal fistulas outside the U.S. Our second
adipose-derived product, Cx611, is undergoing a Phase I/II trial in severe
sepsis - a major cause of mortality in Western world hospitals. Finally,
AlloCSC-01, targeting acute ischemic heart disease, has demonstrated positive
results in a Phase I/II trial in acute myocardial infarction (AMI). TiGenix is
headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more
information, please visit http://www.tigenix.com
Forward-looking information
This press release may contain forward-looking statements and estimates with
respect to the anticipated future performance of TiGenix and the market in which
it operates. Certain of these statements, forecasts and estimates can be
recognised by the use of words such as, without limitation, "believes",
"anticipates", "expects", "intends", "plans", "seeks", "estimates", "may",
"will" and "continue" and similar expressions. They include all matters that are
not historical facts. Such statements, forecasts and estimates are based on
various assumptions and assessments of known and unknown risks, uncertainties
and other factors, which were deemed reasonable when made but may or may not
prove to be correct. Actual events are difficult to predict and may depend upon
factors that are beyond the Company's control. Therefore, actual results, the
financial condition, performance or achievements of TiGenix, or industry
results, may turn out to be materially different from any future results,
performance or achievements expressed or implied by such statements, forecasts
and estimates. Given these uncertainties, no representations are made as to the
accuracy or fairness of such forward-looking statements, forecasts and
estimates. Furthermore, forward-looking statements, forecasts and estimates only
speak as of the date of the publication of this press release. TiGenix disclaims
any obligation to update any such forward-looking statement, forecast or
estimates to reflect any change in the Company's expectations with regard
thereto, or any change in events, conditions or circumstances on which any such
statement, forecast or estimate is based, except to the extent required by
Belgian law.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TiGenix via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 05.04.2017 - 07:01 Uhr
Sprache: Deutsch
News-ID 534520
Anzahl Zeichen: 6103
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 244 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix to participate in key investor conferences in April 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
